{
    "nctId": "NCT02443467",
    "briefTitle": "A Study to Determine the Safety and Tolerability of Herceptin as an Adjuvant Therapy of Early Breast Cancer",
    "officialTitle": "N/A",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Early Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 211,
    "primaryOutcomeMeasure": "Percentage of participants with adverse events",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Female patients \\> or = 18 years of age\n* Human Epidermal Growth Factor Receptor 2 (HER2)-neu overexpression\n* Previously treated with adjuvant antracycline containing chemotherapy\n* Left Ventricular Ejection Fraction (LVEF) \\> 50%\n* Eastern Cooperative Oncology Group (ECOG) score \\< or = 2\n* Life expectancy \\> or = 12 weeks\n\nExclusion Criteria:\n\n* Left Ventricular Ejection Fraction (LVEF) \\< 50%\n* Advanced pulmonary disease\n* Severe dyspnea\n* Abnormal laboratory results within 14 days prior to registration\n* Peripheral neuropathy\n* Presence of Central Nervous System (CNS) metastasis",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}